SBP Group Eyes Innovation as It Shifts Beyond Generics

SBP Group CEO Eric Tse outlined the company's strategic shift from a generics-focused model to drug development during an interview with Stephen Engle at the World Economic Forum's Annual Meeting of the New Champions in Dalian. Tse emphasized innovation as a key driver for SBP Group's future in China's healthcare sector. The company, a long-standing player in the Chinese pharmaceutical market, is looking to leverage new research and development capabilities to create novel therapies. This transition signifies a broader trend within the Chinese pharmaceutical industry, moving towards higher-value, research-intensive drug discovery rather than relying solely on off-patent medications. Tse's remarks suggest a commitment to investing in R&D infrastructure and talent to support this ambitious pivot. The discussion also touched upon the evolving landscape of healthcare policy and market access in China, which are critical factors for pharmaceutical companies aiming to innovate and grow. SBP Group's move is positioned as a response to both domestic market demands and global pharmaceutical trends, seeking to establish a stronger presence in innovative drug markets.